Brown, J., Kaimakliotis, H. Z., Kelly, W. K., Ammons, V., Picus, J., Walling, R., … Hoimes, C. J. (2023). HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Brown, Jason, Hristos Z. Kaimakliotis, William Kevin Kelly, Vikki Ammons, Joel Picus, Radhika Walling, Neda Hashemi-Sadraei, et al. “HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Brown J, Kaimakliotis HZ, Kelly WK, Ammons V, Picus J, Walling R, et al. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Brown, Jason, et al. “HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023.

Brown J, Kaimakliotis HZ, Kelly WK, Ammons V, Picus J, Walling R, Hashemi-Sadraei N, Fu P, Margevicius SP, Adra N, Garcia JA, McKay RR, Hoimes CJ. HCRN GU14-188: Phase Ib/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aNOMO urothelial cancer. JOURNAL OF CLINICAL ONCOLOGY. 2023.